XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 151 filers reported holding XENON PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 3.19 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,409 | -80.8% | 190,033 | -78.8% | 0.02% | -80.3% |
| Q1 2024 | $38,539 | +16.5% | 895,196 | +24.7% | 0.13% | +6.7% |
| Q4 2023 | $33,070 | -15.8% | 717,972 | -37.5% | 0.12% | -19.0% |
| Q3 2023 | $39,256 | -47.9% | 1,149,168 | -41.3% | 0.15% | -43.5% |
| Q2 2023 | $75,404 | +18.2% | 1,958,540 | +9.9% | 0.26% | +13.0% |
| Q1 2023 | $63,800 | -23.8% | 1,782,611 | -16.1% | 0.23% | -23.3% |
| Q4 2022 | $83,749 | -99.9% | 2,124,009 | +11.0% | 0.30% | +19.0% |
| Q3 2022 | $69,090,000 | +22.3% | 1,913,861 | +3.0% | 0.25% | +26.0% |
| Q2 2022 | $56,508,000 | +3.2% | 1,857,596 | +3.7% | 0.20% | +37.0% |
| Q1 2022 | $54,743,000 | -2.4% | 1,790,743 | -0.2% | 0.15% | +14.1% |
| Q4 2021 | $56,079,000 | +870.1% | 1,795,080 | +374.4% | 0.13% | +814.3% |
| Q3 2021 | $5,781,000 | -19.3% | 378,358 | -1.7% | 0.01% | -17.6% |
| Q2 2021 | $7,164,000 | -4.4% | 384,725 | -8.1% | 0.02% | -10.5% |
| Q1 2021 | $7,492,000 | – | 418,550 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,754,266 | $107,388,831 | 7.33% |
| Altium Capital Management LP | 360,600 | $14,059,794 | 5.74% |
| Affinity Asset Advisors, LLC | 994,227 | $38,764,911 | 4.47% |
| First Light Asset Management, LLC | 1,306,260 | $50,931,077 | 4.46% |
| Nan Fung Group Holdings Ltd | 106,680 | $4,159,453 | 4.44% |
| Ally Bridge Group (NY) LLC | 169,369 | $6,603,697 | 3.93% |
| TLS Advisors LLC | 32,956 | $1,285 | 3.22% |
| BRAIDWELL LP | 2,560,573 | $99,836,741 | 3.13% |
| Paradigm Biocapital Advisors LP | 2,043,280 | $79,667,487 | 3.05% |
| BRIDGER MANAGEMENT, LLC | 146,800 | $5,723,732 | 2.94% |